neurometrix_rgb.jpg
NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
September 04, 2020 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be...
neurometrix_rgb.jpg
NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
August 20, 2020 14:11 ET | NeuroMetrix, Inc.
WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of...
neurometrix_rgb.jpg
Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free
August 10, 2020 10:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain (available here) and provided an update on how Quell technology...